20M Stock Chart & Stats
€0.04
>-€0.01(-2.27%)
At close: 4:00 PM EDT
€0.04
>-€0.01(-2.27%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.60K
Market Cap
€19.77M
Enterprise Value€5.06
Total Cash (Recent Filing)€334.00K
Total Debt (Recent Filing)€403.00K
Price to Earnings (P/E)―
Beta-16.76
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding457,002,000
10 Day Avg. Volume3,000
30 Day Avg. Volume1,598
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-199.92
Price to Sales (P/S)433.67
P/FCF Ratio-13.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2026 revenue rebound indicates renewed commercial activity after periods of minimal or zero sales. However, the very small base means sustained growth and customer conversion must still be demonstrated.
Narrowing LossesImproving net losses suggests some progress toward operating discipline and a potentially more manageable cost structure. This is constructive for durability, although margins remain deeply negative and the company is not near break-even.
Platform DiversificationMultiple technology platforms serving agriculture and health-related applications could diversify future revenue sources and broaden the addressable market. Their long-term value depends on translating biological innovation into repeatable commercial adoption.
Bears Say
Negative EquityNegative equity shows accumulated losses have eroded the capital base and materially reduced financial flexibility. Even though absolute debt is modest, debt becomes structurally more burdensome when assets and shareholders’ capital are limited.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate the business is not self-funding. Continued cash outflows may require external financing, asset reductions, or dilution, limiting the company’s ability to invest and withstand execution setbacks.
Weak And Volatile Revenue BaseA minimal, inconsistent revenue base provides little evidence of durable market traction, while large losses relative to sales expose operating leverage risk. The company must establish recurring revenue and improve gross margins before its model can scale sustainably.
20M FAQ
What was Mountain Valley MD’s price range in the past 12 months?
Mountain Valley MD lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Mountain Valley MD’s market cap?
Mountain Valley MD’s market cap is €19.77M.
When is Mountain Valley MD’s upcoming earnings report date?
Mountain Valley MD’s upcoming earnings report date is Sep 02, 2026 which is in 5 days.
How were Mountain Valley MD’s earnings last quarter?
Currently, no data Available
Is Mountain Valley MD overvalued?
According to Wall Street analysts Mountain Valley MD’s price is currently Overvalued.
Does Mountain Valley MD pay dividends?
Mountain Valley MD does not currently pay dividends.
What is Mountain Valley MD’s EPS estimate?
Mountain Valley MD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mountain Valley MD have?
Mountain Valley MD has 457,002,000 shares outstanding.
What happened to Mountain Valley MD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Mountain Valley MD?
Currently, no hedge funds are holding shares in DE:20M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mountain Valley MD
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.